Compare · AUTL vs MRNA
AUTL vs MRNA
Side-by-side comparison of Autolus Therapeutics plc (AUTL) and Moderna Inc. (MRNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AUTL and MRNA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $63.41B, about 97.6x AUTL ($649.4M).
- MRNA has been more active in the news (10 items in the past 4 weeks vs 8 for AUTL).
- MRNA has more recent analyst coverage (25 ratings vs 6 for AUTL).
- Company
- Autolus Therapeutics plc
- Moderna Inc.
- Price
- -
- -
- Market cap
- $649.4M
- $63.41B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 2018
- News (4w)
- 8
- 10
- Recent ratings
- 6
- 25
Autolus Therapeutics plc
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 and AUTO8 for the treatment of multiple myeloma; AUTO1/22 for the treatment of dual-targeting CAR-T; AUTO3NG for the treatment of hematological cancer; AUTO4 and AUTO5 for T cell lymphoma; AUTO6NG for the treatment of programmed T cell therapies; AUTO6 for the treatment of neuroblastoma; and AUTO7 for the treatment of prostate cancer. Autolus Therapeutics plc was founded in 2014 and is headquartered in London, the United Kingdom.
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Latest AUTL
- Amendment: SEC Form SCHEDULE 13G/A filed by Autolus Therapeutics plc
- SEC Form 10-Q filed by Autolus Therapeutics plc
- Autolus Therapeutics plc filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Autolus Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
- Autolus Therapeutics to Report Second Quarter 2026 Financial Results and Host Conference Call on August 11, 2026
- Autolus Therapeutics plc filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- Autolus Therapeutics Reports Preliminary Second Quarter 2026 Net Product Revenue and Announces Credit Facility of up to $250 Million with Perceptive Advisors
- Autolus Therapeutics plc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities
- SEC Form 4 filed by Director Young William D
- SEC Form 4 filed by Director Rao Madduri Ravin
Latest MRNA
- Moderna upgraded by Wolfe Research
- Moderna upgraded by BofA Securities
- Moderna upgraded by William Blair
- Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma
- SEC Form SCHEDULE 13G filed by Moderna Inc.
- Chief Executive Officer Bancel Stephane exercised 751,715 shares at a strike of $19.15 and sold $28,715,011 worth of shares (499,246 units at $57.52) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 6,440,260 units (SEC Form 4) to satisfy withholding tax
- Amendment: SEC Form SCHEDULE 13G/A filed by Moderna Inc.
- Moderna Receives U.S. FDA Approval for Influenza Vaccine mFLUSIVA
- SEC Form 144 filed by Moderna Inc.
- Moderna Announces Initiation of Phase 1 Clinical Trial of mRNA-1469, Moderna's Investigational Vaccine Against Bundibugyo Ebolavirus